Novavax Stock Today
| NVAX Stock | USD 4.15 0.04 0.95% |
Performance2 of 100
| Odds Of DistressOver 63
|
Novavax is trading at 4.15 as of the 25th of April 2024; that is -0.95 percent decrease since the beginning of the trading day. The stock's open price was 4.19. Novavax has more than 63 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Novavax are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of December 1995 | Category Healthcare | Classification Health Care |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. The company has 139.95 M outstanding shares of which 43.77 M shares are now shorted by private and institutional investors with about 5.45 trading days to cover. More on Novavax
Moving together with Novavax Stock
| 0.72 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
| 0.72 | BMY | Bristol Myers Squibb Earnings Call Today | PairCorr |
Moving against Novavax Stock
| 0.46 | ACB | Aurora Cannabis Trending | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Novavax Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novavax's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novavax or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Stanley Erck | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, Dow Jones Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Novavax report their recommendations after researching Novavax's financial statements, talking to executives and customers, or listening in on Novavax's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Novavax. The Novavax consensus assessment is calculated by taking the average forecast from all of the analysts covering Novavax. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Novavax's financial statements, Novavax may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Novavax is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Novavax's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Novavax's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Novavax's financial leverage. It provides some insight into what part of Novavax's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Novavax (NVAX) is traded on NASDAQ Exchange in USA. It is located in 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 and employs 1,543 people. Novavax is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 586.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novavax's market, we take the total number of its shares issued and multiply it by Novavax's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novavax conducts business under Biotechnology sector and is part of Health Care industry. The entity has 139.95 M outstanding shares of which 43.77 M shares are now shorted by private and institutional investors with about 5.45 trading days to cover.
Novavax currently holds about 1.28 B in cash with (717.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Novavax Probability Of Bankruptcy
Ownership AllocationNovavax holds a total of 139.95 Million outstanding shares. Over half of Novavax's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Novavax. Please watch out for any change in the institutional holdings of Novavax as this could mean something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Novavax Ownership Details
Novavax Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Novavax jumping above the current price in 90 days from now is about 74.75%. The Novavax probability density function shows the probability of Novavax stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.5469. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Novavax will likely underperform. Additionally, novavax has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Novavax to move above the current price in 90 days from now is about 74.75 (This Novavax probability density function shows the probability of Novavax Stock to fall within a particular range of prices over 90 days) .
Novavax Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Novavax that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novavax's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novavax's value.| Instituion | Recorded On | Shares | |
| Tsp Capital Management Group/llc | 2023-12-31 | 1.1 M | |
| Jane Street Group, Llc | 2023-12-31 | 1.1 M | |
| Northern Trust Corp | 2023-12-31 | 1 M | |
| Bnp Paribas Arbitrage, Sa | 2023-12-31 | 861.5 K | |
| Bank Of Montreal | 2023-12-31 | 855.8 K | |
| Bmo Capital Markets Corp. | 2023-12-31 | 855.8 K | |
| Barclays Plc | 2023-12-31 | 821.7 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 760.3 K | |
| Allianz Asset Management Ag | 2023-12-31 | 634.7 K | |
| State Street Corporation | 2023-12-31 | 16.8 M | |
| Vanguard Group Inc | 2023-12-31 | 14.6 M |
Novavax Historical Income Statement
Novavax Income Statement is one of the three primary financial statements used for reporting Novavax's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Novavax revenue and expense. Novavax Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Novavax's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 15.1 M in 2024, despite the fact that Operating Income is likely to grow to (394.3 M). View More FundamentalsNovavax Stock Against Markets
Picking the right benchmark for Novavax stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Novavax stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Novavax is critical whether you are bullish or bearish towards Novavax at a given time. Please also check how Novavax's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novavax without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
Novavax Corporate Directors
Novavax corporate directors refer to members of a Novavax board of directors. The board of directors generally takes responsibility for the Novavax's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Novavax's board members must vote for the resolution. The Novavax board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Michael McManus | Independent Director | Profile | |
| Rachel King | Director | Profile | |
| Gary Evans | Independent Director | Profile | |
| Rajiv Modi | Director | Profile |
How to buy Novavax Stock?
Before investing in Novavax, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Novavax. To buy Novavax stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Novavax. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Novavax stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Novavax stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Novavax stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Novavax, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Already Invested in Novavax?
The danger of trading Novavax is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Novavax is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Novavax. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Novavax is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.